Related Experiment Video
Updated: May 24, 2026

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
Published on: June 23, 2015
Chronic kidney disease progression in patients with autosomal dominant polycystic kidney disease
Nayara Panizo1, Marian Goicoechea, Soledad García de Vinuesa
1Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Insights
Autosomal dominant polycystic kidney disease (ADPKD) patients with higher blood pressure and younger age at diagnosis experience faster chronic kidney disease (CKD) progression. Monitoring these factors is crucial for managing ADPKD.
Area of Science:
- Nephrology
- Genetics
- Internal Medicine
Background:
- Autosomal dominant polycystic kidney disease (ADPKD) is a common genetic disorder.
- Chronic kidney disease (CKD) is a significant complication of ADPKD.
- Identifying factors influencing CKD progression in ADPKD is essential for patient management.
Purpose of the Study:
- To analyze factors affecting CKD progression in ADPKD patients.
- To identify predictive markers for renal function decline in ADPKD.
Main Methods:
- A cohort of 101 ADPKD patients was followed for a median of 69 months.
- Primary endpoint: 50% decrease in estimated glomerular filtration rate (eGFR) or initiation of renal replacement therapy.
- Clinical data, blood pressure, and kidney size were assessed.
Main Results:
- 31 patients reached the primary endpoint.
- Higher systolic blood pressure (SBP), diastolic blood pressure (DBP), LDL-cholesterol, creatinine, uricemia, proteinuria, and kidney size were associated with faster progression.
- Younger age at diagnosis and higher SBP were independent predictors of poorer renal outcome.
Conclusions:
- Key factors influencing CKD progression in ADPKD include initial kidney function, proteinuria, renal size, hypercholesterolemia, hyperuricemia, and SBP.
- SBP and younger age at diagnosis are independent predictors of CKD progression in ADPKD.
Objectives:
The aim of this study was to analyse the factors influencing chronic kidney disease (CKD) progression in patients with autosomal dominant polycystic kidney disease (ADPKD).
Material And Method:
We studied 101 patients (mean age: 43 +/- 17.3 years, 43.56% male) followed during a median (interquartile range) follow-up time of 69 (35-128) months from 1997 to 2010. The primary end point was: time to a 50% decrease of estimated glomerular filtration rate (eGFR) (CKD-EPI) since the first-time visit and/or time to initiation of renal replacement therapy, and the annual mean change of eGFR was also analysed. Clinical and demographic data, blood pressure, concomitant medications, and analytical parameters were collected at each visit. Baseline kidney size was also recorded by ultrasound.
Results:
Thirty-one patients achieved the primary end point after a median (IQR) time of 102 (53-131) months. Those patients who achieved the primary end point had higher SBP and DBP (P=0.017 and P=0.001), higher LDL-cholesterol (P=0.011), higher creatinine (P=0.006), higher uricemia (P=0.041), more severe proteinuria (P=0.033) and greater kidney size (P=0.05). The mean annual eGFR change was of -3.52 +/- 7.3ml/min/1.73m2. Forty-nine patients had a rapid decline in renal function: Group A (higher than -3.52ml/min/1.73m2) and 52 patients had a lower renal disease progression: Group B (<-3.2 ml/min/1.73 m2). Adjusted Cox regression analysis showed that higher SBP and younger age at the first visit were independent variables for poorer renal outcome (P=0.026).
Conclusions:
Initial kidney function, proteinuria, renal size, hypercholesterolemia, hyperuricemia, and SBP are the factors that influence CKD progression in ADPKD. SBP and younger age at diagnosis are the only factors that maintain their independent predictive value in a multivariant analysis.
Related Concept Videos
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease III: Interprofessional Care
Diabetic Nephropathy
Chronic Kidney Disease II: Clinical Manifestations
Nephrons
Acute Kidney Injury III: Clinical Manifestations

